Angelina Jolie's celebrity outshines breast cancer risks, study says

Angelina Jolie joins her husband Brad Pitt for a film premiere June 2, 2013, her first public appearance after undergoing a preventive double mastectomy. Credit: Jon Furniss/Invision/AP

In announcing she carried the BRCA1 genetic mutation that significantly increases the risk for breast and ovarian cancer, Jolie not only outlined her reasons for choosing the surgery, she also put a huge spotlight on the medical need for such genetic testing.

For all the newspaper articles that hailed Jolie's decision as inspiring, brave and well-informed, less than a third actually explained the rarity of her condition. Such coverage highlights the challenges of "celebrity medicine," which could have real ramifications for the health system, according to researchers from the University of Alberta.

"There's a lot of research that has shown that celebrities have a big impact on the decisions people make about their own health and the awareness they have about health," said Timothy Caulfield, Canada Research Chair in Health Law Policy and co-author of a study analyzing media coverage of the issue. "Missing the rarity of Jolie's condition is not insignificant. Research also shows women overestimate their risk of , and these kinds of stories can increase fear and concerns, perhaps unnecessarily. That's concerning."

The research team from the U of A's Health Law Institute analyzed coverage from the top newspapers in Canada, the United States and the United Kingdom—103 articles in total. Most depicted Jolie's decision in a positive light, rarely criticizing the phenomenon of celebrity medicine.

Caulfield said the media frenzy about the BRCA1 mutation—since dubbed the "Jolie gene"—comes at a time when access to genetic information is increasing and techniques are becoming more sophisticated, as is our knowledge about the role of genes and human disease. Coverage touched on this, raising questions about access and the high cost of BRCA testing, which has been the subject of legal battles in Canada.

But by focusing more on celebrity, coverage overshadowed arguments for evidence-based assessment of and preventive options. Important medical information was communicated in just 32 per cent of articles, and 68 per cent did not explain the rarity of Jolie's condition.

Research shows that 55 to 65 per cent of women with BRCA1 mutations and 45 per cent with BRCA2 mutations will develop breast cancer during their lives. That falls to just 12 per cent for the general population—a missing fact that, anecdotally at least, is already having an impact on the through increased demand for Jolie-gene testing and preventive mastectomy.

Caulfield says he's not blaming Jolie, whose statements on the issue were quite measured, but he notes that it's tough for health professionals to compete with the power of celebrity, underscoring the importance of effectively communicating risk.

"Even -care providers can struggle in communicating magnitude of risk to their patients, so I think the fact the rarity of Angelina Jolie's situation was not communicated is fascinating and problematic—and something we can learn from."

Caulfield's paper was published Dec. 19 by Nature's Genetics in Medicine.

add to favorites email to friend print save as pdf

Related Stories

Research backs risk-reduction surgery for ovarian cancer

Dec 17, 2013

A study by Manchester scientists backs preventative surgery to improve survival for women who are at greater risk of getting ovarian cancer and suggests it appears helpful for women at risk of getting breast cancer because ...

Recommended for you

The fine line between breast cancer and normal tissues

7 hours ago

Up to 40 percent of patients undergoing breast cancer surgery require additional operations because surgeons may fail to remove all the cancerous tissue in the initial operation. However, researchers at Brigham ...

Pancreatic cancer risk not higher with diabetes Rx DPP-4i

8 hours ago

(HealthDay)—There is no increased short-term pancreatic cancer risk with dipeptidyl-peptidase-4 inhibitors (DPP-4i) compared to sulfonylureas (SU) and thiazolidinediones (TZD) for glycemic control, according ...

Good bowel cleansing is key for high-quality colonoscopy

11 hours ago

The success of a colonoscopy is closely linked to good bowel preparation, with poor bowel prep often resulting in missed precancerous lesions, according to new consensus guidelines released by the U.S. Multi-Society Task ...

New rules for anticancer vaccines

12 hours ago

Scientists have found a way to find the proverbial needle in the cancer antigen haystack, according to a report published in The Journal of Experimental Medicine.

User comments